• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, September 20, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

A breakthrough for understanding GBM: Origin cells for deadly brain tumors identified

Bioengineer by Bioengineer
August 2, 2018
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: KAIST

A new study by KAIST researchers identified where the mutation causing glioblastoma starts. According to the study, neural stem cells away from the tumor mass are the cells of origin that contain mutation drivers for glioblastoma, one of the most aggressive brain tumor. This breakthrough research, reported in Nature on August 1, gives insights for understanding why glioblastomas almost always grow back, even after surgery, and suggests novel ways to treat glioblastoma, which was previously thought to be incurable.

Like most cancers, glioblastoma is treated with surgery to remove as much of the tumor as possible, then radiation and chemotherapy. However, it almost always returns in less than a year and its median survival time is only 15 months. Precision therapeutic approaches targeting tumors themselves didn't lead to any breakthroughs.

Professor Jeong Ho Lee's team at the Graduate School of Medical Scicence and Engineering described direct genetic evidence through the deep sequencing of all triple-matched samples: normal SVZ tissue away from the tumor mass, tumor tissue, and normal cortical tissue. The research team studied 28 patients with glioblastomas and other types of brain tumors who underwent supra-total resection or other surgical resections of tumors, providing access to normal subventricular zone (SVZ) tissue (where neural stem cells are located) away from the tumor mass. The researchers used various deep and single cell sequencing technologies to conduct comparative DNA analysis on the samples from the patient's SVZ tissue and tumors.

They reported that normal SVZ tissue away from the tumor in 56.3% of patients with glioblastoma already contained low-level glioblastoma driver mutations that were observed at high levels in their matching tumors. Furthermore, the research team generated a genome edited mouse carrying glioblastoma mutations in the SVZ and showed that neural stem cells with mutations migrate from the SVZ lead to the development of glioblastomas in distant brain regions.

Professor Lee conducted this study in collaboration with Professor Seok-Gu Kang of the Brain Tumor Center at Severance Hospital of Yonsei University. He said, "It's easier to understand when we compare it to fireworks. Every flare flying around sky can be likened to cancer cells even though the fireworks are triggered on the ground. We found the trigger." The identification of this mutation pathway of glioblastomas will lead to a new paradigm for therapeutic strategies. He added, "Now, we can focus on interrupting the recurrence and evolution of glioblastomas."

Professor Lee has investigated mutations arising in the brain for a decade. He is developing innovative diagnostics and therapeutics for untreatable brain disorders including intractable epilepsy and glioblastoma at a tech-startup, SoVarGen. "All technologies we used during the research were transferred to the company. This research gave us very good momentum to reach the next phase of our startup," he remarked.

###

Media Contact

Younghye Cho
[email protected]
82-423-502-294
@KAISTPR

http://www.kaist.ac.kr

Original Source

http://www.kaist.ac.kr/_prog/_board/?code=ed_news&mode=V&no=83742&upr_ntt_no=83742&site_dvs_cd=en&menu_dvs_cd=060101 http://dx.doi.org/10.1038/s41586-018-0389-3

Share12Tweet7Share2ShareShareShare1

Related Posts

Reticulocalbin-1: Biomarker and Therapy Target in RCC

September 20, 2025

Next-Gen Oncology: Precision Genomics Meets Immuno-Engineering

September 20, 2025

Prostate-Specific Antigen Testing: Past, Present, Future

September 20, 2025

Bisabolol: Natural Anticancer Agent with Therapeutic Promise

September 20, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    156 shares
    Share 62 Tweet 39
  • Physicists Develop Visible Time Crystal for the First Time

    67 shares
    Share 27 Tweet 17
  • Tailored Gene-Editing Technology Emerges as a Promising Treatment for Fatal Pediatric Diseases

    49 shares
    Share 20 Tweet 12
  • Scientists Achieve Ambient-Temperature Light-Induced Heterolytic Hydrogen Dissociation

    48 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Standardized Extract Boosts Immunity in Chemotherapy Mice

Reticulocalbin-1: Biomarker and Therapy Target in RCC

Ag-Doped MnO2 Sea Urchin Structure Boosts Zinc Batteries

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.